In addition, burosumab, a fully humanized FGF23 antibody, was recently approved for treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalcia (TIO) [16, 17]. The gene discussed is FGF23; the disease is X-linked hypophosphatemia.